Bull & Bear

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Watchlist — both sides anchor to the same testable thresholds in the next two FY27 prints, and the controlling-shareholder overhang argues against committing capital before those prints land. Bear carries slightly more weight today: three data points (FX-stripped organic growth ~15%, ICRA's top-3 disclosure at 65% versus management's 59.9%, and the EQT sell-down from 82% to 51% with 100% of the residual pledged) converge on the same "headline overstates the economics" reading. Bull's structural case — the only listed pure-play U.S. healthcare BPM after Capgemini delisted WNS at 16.3× EV/EBITDA, with peer-leading 24.5% margins and a near-zero net-debt sheet — is real but is not setting the marginal price. The decisive test is whether FY27 adj EBITDA margin holds above 22% while top-3 concentration prints below 60%; that one print addresses both the margin-durability and concentration-disclosure tensions.

Bull Case

Bull's scenario value is ~$0.79 over 12-18 months if FY27 prints validate the structural read, derived as 25× FY28E EPS of ~$0.032 and cross-checked against ~12.5× FY28E EV/EBITDA — half the gap between today's 8.7× and the Capgemini-WNS 16.3× strategic take-out. The 25× exit multiple sits below the 38× post-IPO peak (when the business carried more debt and less client diversification) and below Inventurus Knowledge Solutions at ~39× trailing. Bull's disconfirming watchpoint: top-3 concentration ticking back above 62% and adj EBITDA margin slipping below 22% in the same quarter — the configuration consistent with the focus-and-margin premium breaking.

Bear Case

Bear's scenario value is ~$0.32 per share over 12 months if the FX-tailwind and concentration reads play out — the IPO listing-price floor, 25% below the current $0.42. Method: strip ~300 bps of FX-driven margin (24.5% → 21.5%), take the 12% organic-CC top-line guide at face value, derive FY28 EPS of ~$0.021, and apply a 15× P/E — the Indian-BPM discount multiple for a sub-mid-teens grower with falling ROE and a PE-exit overhang. Bear's cover watchpoint mirrors bull's disconfirm: top-3 concentration printing below 55% while adj EBITDA margin holds at or above 25% — evidence the diversification is real and supportive of a re-rating toward the WNS strategic multiple. A second-best forced cover would be a credible strategic bid (Genpact, Cognizant) above $0.58 before the FY27 estimate cuts.

The Real Debate

Verdict

Watchlist. Bear carries more weight today because three independent data points — the 15% FX-stripped organic growth rate, the 500 bps gap between ICRA's top-3 disclosure (65%) and management's KPI (59.9%), and an EQT sell-down with 100% of the residual pledged — converge on the reading that headline numbers overstate the underlying economics, while the price action (death cross 20 Mar 2026, distribution on shrinking volatility) is already pricing it. The central tension is whether the 24.5% operating margin is structural mix or FX-juiced; that variable, testable in the next two FY27 prints, addresses the moat-durability question and the valuation framework on both sides. Bull's structural argument — only listed pure-play in U.S. healthcare BPM with three independent Leader designations and a strategic precedent at 16.3× EV/EBITDA — is genuine; if FY27 Q1/Q2 prints land with margins above 24% and concentration below 60%, much of the bear case loses force. The condition that would shift this verdict from Watchlist toward Lean Long is that print combination — margin ≥24% and top-3 <60% in the same quarter — backed by a clean EQT OFS above $0.53 with mutual-fund absorption; the condition that would shift it to Avoid is the bear's primary configuration (margin <22% and organic CC <12% in the same quarter) or any indication the next OFS clears below $0.44. The durable thesis-breaker is the margin / concentration combination, not any single near-term print; the near-term evidence marker is the pricing and sponsorship of the next EQT block deal, which is highly probable inside 6-12 months.